Scope 3 emissions – a strategic imperative for pharma
Net-zero emissions initiatives have gained traction in recent years, particularly in the pharmaceutical industry.
Pharma has traditionally lagged other industries in emissions commitments, but market pressures from customers and regulators have contributed to shifting emissions targets into focus.
Thirteen of the top 20 pharma companies by revenue have committed to net zero, and among these, over half made their commitments in the past three years.
Scope 3 covers a wide range of emissions that are not directly owned or controlled by a pharma company, both upstream (i.e., pre-production, such as emissions from suppliers) or downstream (i.e., post-production, such as emissions from the disposal of a company’s products) along the value chain.
Check out the rest of the feature here
Source link
#hero #PharmaTimes
